Trials / Completed
CompletedNCT02788006
Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .
Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma .
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Federation Francophone de Cancerologie Digestive · Academic / Other
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter prospective phase II study evaluating regorafenib in older patients with metastatic colorectal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib 160 mg |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2017-08-01
- Completion
- 2017-09-01
- First posted
- 2016-06-02
- Last updated
- 2024-02-23
- Results posted
- 2024-02-23
Locations
16 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02788006. Inclusion in this directory is not an endorsement.